Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have been given a consensus recommendation of “Buy” by the six research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $32.33.

A number of equities analysts have weighed in on OKUR shares. Evercore ISI started coverage on shares of OnKure Therapeutics in a research report on Wednesday, April 30th. They set an “outperform” rating for the company. Oppenheimer reduced their price objective on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Finally, HC Wainwright reduced their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th.

Insider Activity

In other OnKure Therapeutics news, major shareholder Cormorant Asset Management, Lp sold 1,813,439 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $1.85, for a total transaction of $3,354,862.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 1,841,735 shares of company stock worth $3,414,968. 2.30% of the stock is currently owned by company insiders.

Institutional Trading of OnKure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of OKUR. Barclays PLC purchased a new stake in shares of OnKure Therapeutics during the 4th quarter valued at $75,000. ADAR1 Capital Management LLC acquired a new stake in shares of OnKure Therapeutics during the 1st quarter valued at about $43,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of OnKure Therapeutics during the 4th quarter valued at about $104,000. Walleye Capital LLC acquired a new stake in OnKure Therapeutics in the 4th quarter worth about $116,000. Finally, Two Sigma Advisers LP acquired a new stake in OnKure Therapeutics in the 4th quarter worth about $122,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Price Performance

OnKure Therapeutics stock opened at $2.37 on Thursday. OnKure Therapeutics has a one year low of $1.70 and a one year high of $20.00. The firm has a 50-day moving average of $2.49 and a 200-day moving average of $4.98. The company has a market cap of $32.02 million, a price-to-earnings ratio of -0.45 and a beta of 0.42.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.22. As a group, sell-side analysts expect that OnKure Therapeutics will post -4.05 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.